|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: UQCC2 |
Gene summary for UQCC2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | UQCC2 | Gene ID | 84300 |
| Gene name | ubiquinol-cytochrome c reductase complex assembly factor 2 | |
| Gene Alias | C6orf125 | |
| Cytomap | 6p21.31 | |
| Gene Type | protein-coding | GO ID | GO:0002082 | UniProtAcc | Q9BRT2 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 84300 | UQCC2 | GSM4909281 | Human | Breast | IDC | 4.08e-14 | 5.32e-01 | 0.21 |
| 84300 | UQCC2 | GSM4909286 | Human | Breast | IDC | 6.38e-05 | 9.32e-02 | 0.1081 |
| 84300 | UQCC2 | GSM4909288 | Human | Breast | IDC | 4.37e-02 | 1.76e-01 | 0.0988 |
| 84300 | UQCC2 | GSM4909290 | Human | Breast | IDC | 7.52e-04 | 3.15e-01 | 0.2096 |
| 84300 | UQCC2 | GSM4909293 | Human | Breast | IDC | 1.11e-27 | 6.67e-01 | 0.1581 |
| 84300 | UQCC2 | GSM4909294 | Human | Breast | IDC | 1.61e-05 | 3.90e-01 | 0.2022 |
| 84300 | UQCC2 | GSM4909296 | Human | Breast | IDC | 2.15e-04 | 6.00e-02 | 0.1524 |
| 84300 | UQCC2 | GSM4909297 | Human | Breast | IDC | 7.24e-05 | 6.35e-02 | 0.1517 |
| 84300 | UQCC2 | GSM4909298 | Human | Breast | IDC | 3.93e-02 | 6.24e-02 | 0.1551 |
| 84300 | UQCC2 | GSM4909301 | Human | Breast | IDC | 4.28e-04 | 3.74e-01 | 0.1577 |
| 84300 | UQCC2 | GSM4909308 | Human | Breast | IDC | 8.64e-08 | 3.59e-01 | 0.158 |
| 84300 | UQCC2 | GSM4909311 | Human | Breast | IDC | 1.16e-22 | -5.78e-03 | 0.1534 |
| 84300 | UQCC2 | GSM4909312 | Human | Breast | IDC | 5.20e-04 | 8.63e-02 | 0.1552 |
| 84300 | UQCC2 | GSM4909315 | Human | Breast | IDC | 2.48e-07 | 4.69e-01 | 0.21 |
| 84300 | UQCC2 | GSM4909316 | Human | Breast | IDC | 8.40e-10 | 5.86e-01 | 0.21 |
| 84300 | UQCC2 | GSM4909319 | Human | Breast | IDC | 5.69e-31 | -1.56e-02 | 0.1563 |
| 84300 | UQCC2 | GSM4909320 | Human | Breast | IDC | 1.10e-04 | 1.04e-01 | 0.1575 |
| 84300 | UQCC2 | GSM4909321 | Human | Breast | IDC | 3.61e-06 | 3.05e-03 | 0.1559 |
| 84300 | UQCC2 | brca2 | Human | Breast | Precancer | 7.48e-03 | 2.10e-01 | -0.024 |
| 84300 | UQCC2 | NCCBC11 | Human | Breast | DCIS | 6.40e-03 | 2.72e-01 | 0.1232 |
| Page: 1 2 3 4 5 6 7 8 9 10 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:004603427 | Esophagus | HGIN | ATP metabolic process | 101/2587 | 277/18723 | 1.53e-21 | 1.02e-18 | 101 |
| GO:000609120 | Esophagus | HGIN | generation of precursor metabolites and energy | 145/2587 | 490/18723 | 3.41e-20 | 2.04e-17 | 145 |
| GO:000641727 | Esophagus | HGIN | regulation of translation | 139/2587 | 468/18723 | 1.46e-19 | 7.98e-17 | 139 |
| GO:004533320 | Esophagus | HGIN | cellular respiration | 86/2587 | 230/18723 | 2.41e-19 | 1.20e-16 | 86 |
| GO:001598020 | Esophagus | HGIN | energy derivation by oxidation of organic compounds | 105/2587 | 318/18723 | 1.16e-18 | 4.99e-16 | 105 |
| GO:003310820 | Esophagus | HGIN | mitochondrial respiratory chain complex assembly | 47/2587 | 93/18723 | 3.15e-17 | 8.60e-15 | 47 |
| GO:004572720 | Esophagus | HGIN | positive regulation of translation | 49/2587 | 136/18723 | 5.88e-11 | 6.30e-09 | 49 |
| GO:003425020 | Esophagus | HGIN | positive regulation of cellular amide metabolic process | 53/2587 | 162/18723 | 6.01e-10 | 5.15e-08 | 53 |
| GO:00170044 | Esophagus | HGIN | cytochrome complex assembly | 18/2587 | 36/18723 | 2.39e-07 | 1.14e-05 | 18 |
| GO:004346718 | Esophagus | HGIN | regulation of generation of precursor metabolites and energy | 34/2587 | 130/18723 | 1.37e-04 | 2.76e-03 | 34 |
| GO:00325435 | Esophagus | HGIN | mitochondrial translation | 23/2587 | 76/18723 | 1.61e-04 | 3.16e-03 | 23 |
| GO:01400534 | Esophagus | HGIN | mitochondrial gene expression | 27/2587 | 108/18723 | 1.34e-03 | 1.57e-02 | 27 |
| GO:00605379 | Esophagus | HGIN | muscle tissue development | 76/2587 | 403/18723 | 2.67e-03 | 2.63e-02 | 76 |
| GO:00147068 | Esophagus | HGIN | striated muscle tissue development | 72/2587 | 384/18723 | 3.94e-03 | 3.56e-02 | 72 |
| GO:0006091110 | Esophagus | ESCC | generation of precursor metabolites and energy | 331/8552 | 490/18723 | 3.86e-23 | 8.45e-21 | 331 |
| GO:0045333110 | Esophagus | ESCC | cellular respiration | 173/8552 | 230/18723 | 4.53e-20 | 5.99e-18 | 173 |
| GO:0033108110 | Esophagus | ESCC | mitochondrial respiratory chain complex assembly | 83/8552 | 93/18723 | 9.56e-19 | 1.05e-16 | 83 |
| GO:014005313 | Esophagus | ESCC | mitochondrial gene expression | 93/8552 | 108/18723 | 1.96e-18 | 2.03e-16 | 93 |
| GO:0009060110 | Esophagus | ESCC | aerobic respiration | 145/8552 | 189/18723 | 2.16e-18 | 2.21e-16 | 145 |
| GO:0015980110 | Esophagus | ESCC | energy derivation by oxidation of organic compounds | 220/8552 | 318/18723 | 1.20e-17 | 1.09e-15 | 220 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| UQCC2 | SNV | Missense_Mutation | c.103G>T | p.Val35Leu | p.V35L | Q9BRT2 | protein_coding | deleterious(0.03) | probably_damaging(0.99) | TCGA-A2-A25D-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen | SD | |
| UQCC2 | SNV | Missense_Mutation | rs531733294 | c.182N>T | p.Ala61Val | p.A61V | Q9BRT2 | protein_coding | tolerated(0.37) | benign(0.104) | TCGA-AZ-4313-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| UQCC2 | SNV | Missense_Mutation | c.221N>A | p.Arg74His | p.R74H | Q9BRT2 | protein_coding | tolerated(0.05) | benign(0.061) | TCGA-AZ-6598-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| UQCC2 | SNV | Missense_Mutation | novel | c.200N>G | p.Tyr67Cys | p.Y67C | Q9BRT2 | protein_coding | deleterious(0.01) | probably_damaging(0.964) | TCGA-AG-A00Y-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| UQCC2 | SNV | Missense_Mutation | novel | c.173N>G | p.Glu58Gly | p.E58G | Q9BRT2 | protein_coding | deleterious(0.01) | benign(0.053) | TCGA-AG-A02X-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| UQCC2 | SNV | Missense_Mutation | c.199N>G | p.Tyr67Asp | p.Y67D | Q9BRT2 | protein_coding | deleterious(0.01) | possibly_damaging(0.899) | TCGA-AP-A056-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| UQCC2 | SNV | Missense_Mutation | novel | c.232A>G | p.Thr78Ala | p.T78A | Q9BRT2 | protein_coding | deleterious(0) | probably_damaging(0.911) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
| UQCC2 | SNV | Missense_Mutation | c.60N>C | p.Glu20Asp | p.E20D | Q9BRT2 | protein_coding | tolerated(0.24) | benign(0.275) | TCGA-55-A48Y-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Chemotherapy | carboplatin | CR | |
| UQCC2 | SNV | Missense_Mutation | novel | c.255G>T | p.Leu85Phe | p.L85F | Q9BRT2 | protein_coding | deleterious(0.04) | benign(0.203) | TCGA-CN-6010-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | cisplatin | PD |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |